Elutia Inc. Class A Common Stock (ELUT) is a publicly traded Healthcare sector company. As of May 21, 2026, ELUT trades at $1.18 with a market cap of $48.63M and a P/E ratio of 0.91. ELUT moved +6.70% today. Year to date, ELUT is +92.18%; over the trailing twelve months it is -35.16%. Its 52-week range spans $0.50 to $5.12. Analyst consensus is buy with an average price target of $5.00. Rallies surfaces ELUT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Elutia Reports Q1 Sales Growth to $3.1M, Gross Margin Rises to 58%, Net Loss Widens: Elutia reported Q1 net sales of $3.1 million, up 6% year-over-year, with gross margins rising to 58% (67% adjusted) even as SimpliDerm revenue fell to $2.1 million and net loss widened to $7.5 million. The company closed with $36.5 million cash and escrow, advancing its NXT-41x FDA submission.
| Metric | Value |
|---|---|
| Price | $1.18 |
| Market Cap | $48.63M |
| P/E Ratio | 0.91 |
| EPS | $1.29 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.12 |
| 52-Week Low | $0.50 |
| Volume | 120.77K |
| Avg Volume | 0 |
| Revenue (TTM) | $12.29M |
| Net Income | $53.38M |
| Gross Margin | 53.66% |
1 analysts cover ELUT: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $5.00.